Quality and Efficacy Concerns with Generics in Treatment of Hepatitis C with Directly Acting Antivirals
Bader Faiyaz Zuberi
Journal of the Dow University of Health Sciences · 2017
doi:10.36570/jduhs.2017.2.001 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Treating hepatitis C has never been so convenient after the advent of Directly Acting Antivirals (DAA). Convenience is at both ends; for the doctors to prescribe and for patients to comply due to all oral therapy with few adverse effects. Many are already in market, these include, Sofosbuvir, Declastavir & Velpastavir while many others are in pipeline.
Abstract licence: CC BY-NC
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.